| Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, ... Journal of clinical oncology 28 (31), 4722-4729, 2010 | 983 | 2010 |
| Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma PE Fecci, DA Mitchell, JF Whitesides, W Xie, AH Friedman, GE Archer, ... Cancer research 66 (6), 3294-3302, 2006 | 720 | 2006 |
| Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients DA Mitchell, KA Batich, MD Gunn, MN Huang, L Sanchez-Perez, SK Nair, ... Nature 519 (7543), 366-369, 2015 | 644 | 2015 |
| A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study J Schuster, RK Lai, LD Recht, DA Reardon, NA Paleologos, MD Groves, ... Neuro-oncology 17 (6), 854-861, 2015 | 483 | 2015 |
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma JH Sampson, KD Aldape, GE Archer, A Coan, A Desjardins, AH Friedman, ... Neuro-oncology 13 (3), 324-333, 2011 | 428 | 2011 |
| Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function PE Fecci, H Ochiai, DA Mitchell, PM Grossi, AE Sweeney, GE Archer, ... Clinical cancer research 13 (7), 2158-2167, 2007 | 422 | 2007 |
| An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme JH Sampson, GE Archer, DA Mitchell, AB Heimberger, JE Herndon, ... Molecular cancer therapeutics 8 (10), 2773-2779, 2009 | 364 | 2009 |
| Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion A Lal, CA Glazer, HM Martinson, HS Friedman, GE Archer, JH Sampson, ... Cancer research 62 (12), 3335-3339, 2002 | 356 | 2002 |
| Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination KA Batich, EA Reap, GE Archer, L Sanchez-Perez, SK Nair, ... Clinical Cancer Research 23 (8), 1898-1909, 2017 | 346 | 2017 |
| Poor drug distribution as a possible explanation for the results of the PRECISE trial JH Sampson, G Archer, C Pedain, E Wembacher-Schröder, M Westphal, ... Journal of neurosurgery 113 (2), 301-309, 2010 | 306 | 2010 |
| Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the … JH Sampson, G Akabani, GE Archer, DD Bigner, MS Berger, AH Friedman, ... Journal of neuro-oncology 65 (1), 27-35, 2003 | 297 | 2003 |
| Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors AB Heimberger, LE Crotty, GE Archer, KR Hess, CJ Wikstrand, ... Clinical cancer research 9 (11), 4247-4254, 2003 | 293 | 2003 |
| Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors JH Sampson, LE Crotty, S Lee, GE Archer, DM Ashley, CJ Wikstrand, ... Proceedings of the National Academy of Sciences 97 (13), 7503-7508, 2000 | 260 | 2000 |
| The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target CJ Wikstrand, CJ Reist, GE Archer, MR Zalutsky, DD Bigner Journal of neurovirology 4 (2), 148-158, 1998 | 257 | 1998 |
| Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa) AB Heimberger, CA Learn, GE Archer, RE McLendon, TA Chewning, ... Clinical Cancer Research 8 (11), 3496-3502, 2002 | 239 | 2002 |
| Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma JH Sampson, GE Archer, DA Mitchell, AB Heimberger, DD Bigner Seminars in immunology 20 (5), 267-275, 2008 | 227 | 2008 |
| Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme CA Learn, TL Hartzell, CJ Wikstrand, GE Archer, JN Rich, AH Friedman, ... Clinical cancer research 10 (9), 3216-3224, 2004 | 205 | 2004 |
| EGFRvIII‐targeted vaccination therapy of malignant glioma BD Choi, GE Archer, DA Mitchell, AB Heimberger, RE McLendon, ... Brain pathology 19 (4), 713-723, 2009 | 180 | 2009 |
| Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma BD Choi, CT Kuan, M Cai, GE Archer, DA Mitchell, PC Gedeon, ... Proceedings of the National Academy of Sciences 110 (1), 270-275, 2013 | 177 | 2013 |
| Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma AB Heimberger, LE Crotty, GE Archer, RE McLendon, A Friedman, ... Journal of neuroimmunology 103 (1), 16-25, 2000 | 176 | 2000 |
